IXICO PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.255 GBX | -0.62% |
|
-4.85% | -41.96% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 5.2M 6.59M | Sales 2025 * | - | Capitalization | 3.53M 4.47M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -2.53M | Net income 2025 * | - | EV / Sales 2024 * | 0.41 x |
| Net cash position 2024 * | 1.4M 1.77M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.33
x | P/E ratio 2025 * |
-
| Employees | 89 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on IXICO plc
More press releases
| 1 day | -0.62% | ||
| 1 week | -4.85% | ||
| Current month | -10.71% | ||
| 1 month | -17.09% | ||
| 3 months | -21.57% | ||
| 6 months | -53.19% | ||
| Current year | -41.96% |
1 week
7.05
7.50
1 month
7.059.00
Current year
6.3513.50
1 year
6.3521.00
3 years
6.3594.20
5 years
6.35127.00
10 years
6.35127.00
| Managers | Title | Age | Since |
|---|---|---|---|
Giulio Cerroni
CEO | Chief Executive Officer | 63 | 17-02-05 |
| Director of Finance/CFO | 47 | 19-05-30 | |
Charles Spicer
CHM | Chairman | 59 | 13-10-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 13-10-13 |
| Director/Board Member | 49 | 16-09-15 | |
Dipti Amin
BRD | Director/Board Member | 60 | 23-10-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 7.255 | -0.62% | 2 |
| 24-05-15 | 7.3 | -1.02% | 50,016 |
| 24-05-14 | 7.375 | 0.00% | 24,503 |
| 24-05-13 | 7.375 | 0.00% | 12,820 |
| 24-05-10 | 7.375 | -3.28% | 65,696 |
Delayed Quote London S.E., May 16, 2024 at 03:11 am EDT
More quotes
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Calendar
2024-05-21
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -41.96% | 4.47M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.96% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- IXI Stock
